resistance area is abaut 16.20 $
Now the question is what is the support area ? Personally, I think that 7.7 $ Entry into the black scenario.I think that at one time it tested in future.
Out of money!!! Each research clinical-stage pharmaceutical company is out of money.
we have raised net cash proceeds of $78.6 million from the sale of $43.8 million of convertible preferred stock and $34.8 million of convertible notes
we had a deficit accumulated during the development stage of $84.8 million
We received net proceeds from the initial public offering of approximately $68.3 million, after deducting underwriting discounts and commissions of $5.4 million and expenses of $3.6 million.
We anticipate that we will use approximately $37.4 million of the net proceeds from the offering for direct clinical and non-clinical costs associated with the completion of Phase 3 registration trials and filing of a New Drug Application with the Food and Drug Administration for our AR-13324 product candidate and approximately $9.8 million for direct clinical and non-clinical costs associated with the completion of the Phase 2b clinical trial and Phase 3 enabling activities for our PG324 product candidate.
Research and development expenses increased by $1.4 million for the nine months ended September 30, 2013 as compared to the nine months ended September 30, 2012. The net increase was primarily due to higher direct clinical costs of $2.4 million offset by a decrease in direct non-clinical costs of $0.9 million. The remaining difference is due to the change in unallocated expenses including employee salary and related expenses. The direct clinical costs for AR-13324 increased by $0.6 million due to activity related to its Phase 2b clinical trial.
initial offering price of $10.00 per share
Fibonacci Retracements are 61.8% and 38.2%.
$10.00 per share 61.8% 16.18$
38.2% 13.82$ reversal alert zone
I hurt myself today
To see if I still feel
I focus on the pain (when he collapsed PYMX)
The only thing that's real
The needle tears a hole
The old familiar sting
Try to kill it all away
But I remember everything in PolyMedix
What have I become
My sweetest friend
Everyone I know
goes away and money as well
In the end
And you could have it all
My empire of dirt
I will let you down
I will make you hurt
I wear this crown of thorns
Upon my liar's chair
Full of broken thoughts
I cannot repair
Beneath the stains of time
The feelings disappears such as love poly
You are someone else
I am still right here in CTIX
What have I become
My sweetest friend
Everyone I know
goes away (mulletman99, brockintont,survtech and my best friend bocamp1)
In the end in PolyMedix
And you could have it all
My empire of dirt
I will let you down
I will make you hurt
If I could start again in CTIX
A million miles away
I would keep myself
I would find a way and $$$$$$$
Unfortunately,CTIX in OTCMKTS:CTIX
OTCMKTS- garbage market Therefore, it is possible to all ! If not NASDAQ MARKET
Who Should Join OTCQX?
OTCQX is also for U.S. companies seeking to build a more stable valuation and generate greater visibility in the investment community in a cost-effective manner.
OTCQX U.S. is for high growth and early stage companies incorporated in the U.S. that want to develop their operations and investor base in a cost-effective manner. The qualification standards support a transparent marketplace with financial information disclosure made through the SEC's EDGAR system, or for companies not required to register with the SEC, through OTC Market Group's OTC Disclosure & News Service. Companies are required to meet minimum financial standards and the OTCQX security must have a bid price of at least $0.10. To learn more about qualifying for OTCQX U.S., see: OTCQX U.S. Overview.
Bady often agree with you. Maybe it really is possible to brilacidin working or not
For manufacturing technology and computer modeling would be a good idea to run at least in theory, because they are performed on the new models have new drugs.
Computer modeling of drug that is the future.
And finally the reality of one big nothing ZERO 0
Big eyes, a lot of smart experts talking about enormous wealth LAS VEGAS someone said.
after Loss BIGAS
Now it is clear how bad management was PYMX Roche To Partner With Cellceutix Corporation (CTIX) In Phase 2B Clinical Trials Of New Antibiotic Wonder Drug Brilacidin
Crazy bell-ringer was right. There's money to be made in these parts
Where are they now old friends polyshareholders and what they think now?
quietly sit in solitude and curse fools of poly
said yes and died
NASDAQ creates a "real" market. Many of the larger funds, more conservtive investors, "widows & orphans", etc. are not allowed to invest in OTC stocks. The OTC market is simply very limited and thus does not have enough serious investors chasing your shares.
Where is it? NASDAQ Listing.
This price is a joke right now.
Big Pharma know they are out there, know they are looking for partners, know they have nothing to license, know they are looking for financing and know they have great potential. CTIX is estimating it will cost over 50 million to get them past Phase III.
Fact sheets updated?.
Rapid Action-Brilaciden time kills 30 min-4 hours. Bacterial death committed with only 2 minutes of drug exposure. Rapid killing at 0.25 MIC. 17 hour post-antibiotic effects. Also active in stationary phase bacteria.
Brilaciden is active against stationary phase bacteria plus sub-MIC activity. This is a major distinction vs. daptomycin and most other antibiotics. It's also encouraging for short course of therapy and active against a wide range of pathogens, anti-inflammatory plus anti-biofilm means more robust efficacy in certain difficult infections (endocarditis, pneumonia) and oral mucositis.
Will we see FDA-approved fast-tracking of PMX-30063 ?.
It's a money problem now.....It has become very clear that the future of CTIX isn't dependent on the science, but the availability of financing. But science and money go hand in hand. There is smart money out there, but I don't see it coming into CTIX
"So, just get back to work and get those results ... 63 released."
Melinta Therapeutics, based on a legacy of Nobel Prize-winning science, is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and is initiating Phase 3 for gonorrhea.
Bad Bugs, No Drugs: No ESKAPE! An Update
from the Infectious Diseases Society of America
Where is the Brilacidin? nowhere!
Rule #1: Never fall in love with a stock. It will eat your heart out and then spit you out. This must be your first love newbie. Sorry to be harsh, its the trend my friend. Watch and learn.
An entire new class of peptide mimetics, namely α-AApeptides, with broad spectrum activity against both Gram-negative and Gram-positive bacteria and fungi, was recently reported. AApeptides are oligomers of N-acylated-N-aminoethyl amino acids, designed on the principle of globally amphipathic structures as drivers for membrane-active antimicrobial compounds (Figure (Figure1D).1D). “Coupled with straightforward solid phase synthesis, virtually limitless structural possibilities, low cost of production, simple tunability and programmability, and resistance to protease hydrolysis, α-AApeptides may lead to a new class of antimicrobial peptidomimetics,” remarked authors (Padhee et al., 2011). In their hands, one of the synthesized oligomers displayed minimal inhibitory concentration (MIC) values – defined as the lowest inhibitor concentration that completely inhibits the growth of microbes during a 24h incubation period at 37°C – as low as 2.1μg/ml against the Gram-negative E. coli and 0.9μg/ml against the Gram-positive Bacillus subtilis, respectively, while being non-hemolytic (Padhee et al., 2011). These levels of activities are equal to or better than those of most natural AMPs and peptidomimetics reported so far. The same group, led by Jianfeng Cai at the University of South Florida in Tampa, FL, USA, lately reported the design and synthesis of lipidated γ-AApeptides (Figure (Figure1E)1E) as antimicrobial agents (Niu et al., 2012). According to the authors, the introduction of an unsaturated lipid chain significantly decreased hemolytic activity, thereby enhancing target selectivity. One of the synthesized lipo-γ-AApeptides did not induce drug resistance in methicillin-resistant S. aureus, even after 17 passages (Niu et al., 2012).
-may have to start with this-
On Friday, September 27 from 1:00 PM - 2:00 PM (EDT), FDA will present a webinar on new Draft Guidance for Industry Antibacterial Therapies for Patients with Unmet Medical Need for the Treatment of Serious Bacterial Diseases.
Joseph G. Toerner, MD, MPH
Associate Director for Medical Affairs
Office of Antimicrobial Products
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
For questions concerning the webinar, please contact Marsha Holloman (301-796-0731).
Of the 9.4 million new tuberculosis (TB) cases diagnosed each year, approximately 5% are multidrug resistant (MDR). MDR-TB treatment is demanding for patients, requiring a complex treatment course lasting 18–24 months, and using a minimum of five different antibiotics that often add up to more than 20 tablets a day.
One of the group of drugs required are injectable antibiotics that must be given for a minimum of 8 months.
These drugs—kanamycin, amikacin, and capreomycin—are key to any treatment regimen for MDR-TB.
The bacteria causing multidrug-resistant TB (MDR-TB) are resistant to the most potent anti-TB drugs like isoniazid and rifampicin. Extensively drug-resistant TB (XDR-TB) is even more deadly and resistant to any of the second-line anti-TB injectable drugs. The statistics on trends in morbidity and mortality attributed to MDR-TB, and reported by WHO is quite scary. According to them, every year about 440,000 MDR-TB cases are estimated to have appeared globally, and out of which about 150,000 patients die7. India has the highest MDR-TB burden in the world. It is estimated that about 73,000 MDR-TB cases are emerging every year. Moreover, the average cost of treating a patient with MDR-TB is estimated to be about US $9000 as compared to $19 for drug-sensitive TB8. Hospital acquired methicillin-resistant Staphylococcus aureus (MRSA) is estimated to cause ~19,000 deaths per year in the United States9. Apart from their high mortality rate, MRSA infections lead to an estimated $3 billion to $4 billion of additional health care costs per year. NDM-1 (New Delhi metallo-beta-lactamase-1), is a gene carried by bacteria, which is responsible for producing an enzyme, carbapenemase, within the bacteria making them resistant to almost all the present antibiotics
(1) if something can go wrong, it will do so just before your grant is up for review;
(2) if the reading on your detector is correct, then you have forgot to plug it in;
(3) if several things can go wrong then they will do so all at the same time;
(4) if nothing can go wrong with your experiment, something still will;
(5) left unto itself, your experiment will go from bad to worse; on the other hand, if you pay attention to the experiment then it will take three times longer to complete than you thought it would;
(6) Nature is both subtle and malicious (Murphy stole this one from Albert Einstein);
(7) a straight line will never fit your data, and using a wiggly line will result in the rejection by referees of the publication of work;
(8) if you make a great discovery today, you will find a major error in your methods tomorrow (experienced experimentalists call this effect "here today, gone tomorrow");
(9) in contrast to a radio, banging your apparatus when you are at peak frustration will not fix it but permanently break it (for this reason, it is important for experimentalists to remain calm at all times);
(10) when your experiment is just about to succeed, you will run out of grant money.
In short, in a scientific experiment, anything that can go wrong will go wrong.
You said it very well kevinllieno
1-Poly does not own anything.PMX 30063 the property of the University Pennsylvania,Proprietary Rights.In January 2003, we entered into a Patent License Agreement with the University of Pennsylvania, or Penn. Under the terms of the agreement, we were granted an exclusive, worldwide royalty-bearing license to use, make and sell products utilizing seven of Penn’s issued patents or pending patent applications for the life of such patents.
We also entered into a Software License Agreement with Penn in May 2003. Under the terms of the agreement, Penn granted us a non-exclusive, royalty-free license to use three software programs and an exclusive, royalty-free license to three patent applications relating to such software programs. The software programs and patents covered by the agreement include a suite of proprietary computational algorithms that we use
It follows from this, that the CTIX done a deal with the University of Pennsylvania
2-Most of the research has been done in Eastern Europe.Believe that in Eastern Europe, nothing happens without the high politics and corruption.Not to believe all the research and there is a high probability of connection with local investigators.
3-They never talked about what cost and why Eastern Europe. There are easily laundered money and hides all the financial facts and researchIt Is true that only Nic knew all backgrounds and had connections in Eastern Europe.
4-What is the most important thing Worldwide exclusive licenses to a computational drug design technology (CDDT)
PolyMedix’s CDDT consists of the following four computational models, which are proprietary to PolyMedix and were exclusively licensed from the University of Pennsylvania, and which are covered by three patents:GOLDYN,COSMOS,SUCCEED;PACE
This is the technology of the 21st century AND THIS IS A TRUE VALUE.
bravo bravo servtech finally share the same opinion after such a long journey come together in a new company CTIX. Truly amazing company with 2 employees zero debt and one product in one phase and another product 2b in which nobody wants hahaha where you get franchise of all for $ 2M and you put in the past, circa 115 M $ Yes you really no rush.
I recall that at the beginning of the share was PYMX $ 5
yes i picked the wrong horse yes i go short in spite to make my money back but not whith CTIX
yes i lose the money investing in polym and I can think of how much it was worth at the end of PYMX.
and what concerns me most ANY large COMPANY not bought BRILACIDIN if it is really a good product.